Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
1(25%)
Results Posted
0%(0 trials)

Phase Distribution

Ph not_applicable
1
25%
Ph phase_3
1
25%
Ph phase_4
1
25%

Phase Distribution

0

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution3 total trials
Phase 3Large-scale testing
1(33.3%)
Phase 4Post-market surveillance
1(33.3%)
N/ANon-phased studies
1(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(2)
Other(1)

Detailed Status

Completed2
Recruiting1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 31 (33.3%)
Phase 41 (33.3%)
N/A1 (33.3%)

Trials by Status

recruiting125%
completed250%
unknown125%

Recent Activity

1 active trials
Showing 4 of 4
recruitingphase_3

Study of Tamsulosin, Solifenacin and Mirabegron in Alleviating Ureteral Stent-related Symptoms

NCT06803030
unknown

Effect of beta3-adrenoceptor Agonist on Patients With Overactive Bladder and as a Urinary Biomarker

NCT04693897
completednot_applicable

Compare Sudden Stopping and Weaning of Anticholinergics in Recurrence of OAB Symptoms

NCT04064619
completedphase_4

Efficacy and Safety of the Mirabegron Compared With Solifenacin in Treatment of Overactive Bladder

NCT03558919

Clinical Trials (4)

Showing 4 of 4 trials
NCT06803030Phase 3

Study of Tamsulosin, Solifenacin and Mirabegron in Alleviating Ureteral Stent-related Symptoms

Recruiting
NCT04693897

Effect of beta3-adrenoceptor Agonist on Patients With Overactive Bladder and as a Urinary Biomarker

Unknown
NCT04064619Not Applicable

Compare Sudden Stopping and Weaning of Anticholinergics in Recurrence of OAB Symptoms

Completed
NCT03558919Phase 4

Efficacy and Safety of the Mirabegron Compared With Solifenacin in Treatment of Overactive Bladder

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4